Paragon 28, Inc. (NYSE: FNA) Stock Competitors & Peer Comparison
See FNA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for FNA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FNA | $13.09 | +0.00% | 1.1B | -19.83 | -$0.66 | N/A |
| ABT | $111.27 | +0.32% | 192.6B | 21.36 | $5.21 | +2.23% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $341.09 | -1.76% | 130.8B | 25.47 | $13.39 | +1.02% |
| MDT | $90.58 | -0.20% | 116B | 16.38 | $5.53 | +3.14% |
| BSX | $51.69 | +0.53% | 76.9B | 16.68 | $3.10 | N/A |
| EW | $92.56 | -0.53% | 53.3B | 34.29 | $2.70 | N/A |
| DXCM | $91.48 | +0.75% | 34.5B | 39.26 | $2.33 | N/A |
| RMD | $226.74 | +0.33% | 32.9B | 21.06 | $10.77 | +1.05% |
| PHG | $27.38 | +2.16% | 26.8B | 15.64 | $1.75 | +3.62% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
FNA vs ABT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ABT has a market cap of 192.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ABT trades at $111.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ABT's P/E ratio is 21.36. In terms of profitability, FNA's ROE is -0.35%, compared to ABT's ROE of +0.11%. Regarding short-term risk, FNA is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
FNA vs BSX-PA Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, FNA's ROE is -0.35%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, FNA is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
FNA vs SYK Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SYK has a market cap of 130.8B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SYK trades at $341.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SYK's P/E ratio is 25.47. In terms of profitability, FNA's ROE is -0.35%, compared to SYK's ROE of +0.16%. Regarding short-term risk, FNA is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for FNA.Check SYK's competition here
Medtronic plc (NYSE: MDT)
FNA vs MDT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, MDT has a market cap of 116B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while MDT trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas MDT's P/E ratio is 16.38. In terms of profitability, FNA's ROE is -0.35%, compared to MDT's ROE of +0.10%. Regarding short-term risk, FNA is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
FNA vs BSX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BSX has a market cap of 76.9B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BSX trades at $51.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BSX's P/E ratio is 16.68. In terms of profitability, FNA's ROE is -0.35%, compared to BSX's ROE of +0.15%. Regarding short-term risk, FNA is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
FNA vs EW Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, EW has a market cap of 53.3B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while EW trades at $92.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas EW's P/E ratio is 34.29. In terms of profitability, FNA's ROE is -0.35%, compared to EW's ROE of +0.10%. Regarding short-term risk, FNA is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for FNA.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
FNA vs DXCM Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, DXCM has a market cap of 34.5B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while DXCM trades at $91.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas DXCM's P/E ratio is 39.26. In terms of profitability, FNA's ROE is -0.35%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, FNA is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for FNA.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
FNA vs RMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while RMD trades at $226.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas RMD's P/E ratio is 21.06. In terms of profitability, FNA's ROE is -0.35%, compared to RMD's ROE of +0.24%. Regarding short-term risk, FNA is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
FNA vs PHG Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PHG trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PHG's P/E ratio is 15.64. In terms of profitability, FNA's ROE is -0.35%, compared to PHG's ROE of +0.10%. Regarding short-term risk, FNA is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
FNA vs ZBH Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ZBH trades at $99.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ZBH's P/E ratio is 11.74. In terms of profitability, FNA's ROE is -0.35%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, FNA is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
FNA vs ABMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ABMD's P/E ratio is 65.36. In terms of profitability, FNA's ROE is -0.35%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, FNA is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for FNA.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
FNA vs PEN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PEN trades at $326.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PEN's P/E ratio is 85.36. In terms of profitability, FNA's ROE is -0.35%, compared to PEN's ROE of +0.11%. Regarding short-term risk, FNA is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
FNA vs SNN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SNN trades at $30.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SNN's P/E ratio is 14.17. In terms of profitability, FNA's ROE is -0.35%, compared to SNN's ROE of +0.12%. Regarding short-term risk, FNA is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
FNA vs ALGN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ALGN has a market cap of 12.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ALGN trades at $176.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ALGN's P/E ratio is 16.06. In terms of profitability, FNA's ROE is -0.35%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, FNA is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ALGN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
FNA vs SWAV Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SWAV's P/E ratio is 78.76. In terms of profitability, FNA's ROE is -0.35%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, FNA is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for FNA.Check SWAV's competition here
Globus Medical, Inc. (NYSE: GMED)
FNA vs GMED Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while GMED trades at $85.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas GMED's P/E ratio is 19.36. In terms of profitability, FNA's ROE is -0.35%, compared to GMED's ROE of +0.12%. Regarding short-term risk, FNA is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for FNA.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
FNA vs GKOS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, GKOS has a market cap of 11.2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while GKOS trades at $189.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas GKOS's P/E ratio is -220.30. In terms of profitability, FNA's ROE is -0.35%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, FNA is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for FNA.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
FNA vs PODD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PODD trades at $146.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PODD's P/E ratio is 24.95. In terms of profitability, FNA's ROE is -0.35%, compared to PODD's ROE of +0.27%. Regarding short-term risk, FNA is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
FNA vs BIO Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BIO has a market cap of 9.7B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BIO trades at $361.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BIO's P/E ratio is 38.93. In terms of profitability, FNA's ROE is -0.35%, compared to BIO's ROE of +0.03%. Regarding short-term risk, FNA is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
FNA vs BIO-B Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BIO-B trades at $348.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, FNA's ROE is -0.35%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, FNA is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for FNA.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
FNA vs MASI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas MASI's P/E ratio is 44.43. In terms of profitability, FNA's ROE is -0.35%, compared to MASI's ROE of +0.09%. Regarding short-term risk, FNA is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for FNA.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
FNA vs BRKR Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BRKR trades at $57.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BRKR's P/E ratio is 29.11. In terms of profitability, FNA's ROE is -0.35%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, FNA is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
FNA vs NARI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas NARI's P/E ratio is -59.24. In terms of profitability, FNA's ROE is -0.35%, compared to NARI's ROE of -0.00%. Regarding short-term risk, FNA is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for FNA.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
FNA vs LIVN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while LIVN trades at $82.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas LIVN's P/E ratio is 19.19. In terms of profitability, FNA's ROE is -0.35%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, FNA is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
FNA vs ITGR Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ITGR trades at $125.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ITGR's P/E ratio is 19.69. In terms of profitability, FNA's ROE is -0.35%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, FNA is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ITGR's competition here
Haemonetics Corporation (NYSE: HAE)
FNA vs HAE Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, HAE has a market cap of 4.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while HAE trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas HAE's P/E ratio is 18.06. In terms of profitability, FNA's ROE is -0.35%, compared to HAE's ROE of +0.11%. Regarding short-term risk, FNA is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for FNA.Check HAE's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
FNA vs IRTC Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while IRTC trades at $123.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas IRTC's P/E ratio is -192.44. In terms of profitability, FNA's ROE is -0.35%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, FNA is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for FNA.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
FNA vs AXNX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas AXNX's P/E ratio is -709.80. In terms of profitability, FNA's ROE is -0.35%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, FNA is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for FNA.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
FNA vs TMDX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while TMDX trades at $89.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas TMDX's P/E ratio is 45.50. In terms of profitability, FNA's ROE is -0.35%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, FNA is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for FNA.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
FNA vs AXGN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while AXGN trades at $48.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas AXGN's P/E ratio is 126.45. In terms of profitability, FNA's ROE is -0.35%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, FNA is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
FNA vs UFPT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while UFPT trades at $319.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas UFPT's P/E ratio is 32.67. In terms of profitability, FNA's ROE is -0.35%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, FNA is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
FNA vs BFLY Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BFLY trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BFLY's P/E ratio is -36.79. In terms of profitability, FNA's ROE is -0.35%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, FNA is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
FNA vs ESTA Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ESTA trades at $75.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ESTA's P/E ratio is -59.99. In terms of profitability, FNA's ROE is -0.35%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, FNA is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
FNA vs NUVA Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas NUVA's P/E ratio is 75.00. In terms of profitability, FNA's ROE is -0.35%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, FNA is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for FNA.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
FNA vs NVCR Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while NVCR trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas NVCR's P/E ratio is -11.36. In terms of profitability, FNA's ROE is -0.35%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, FNA is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for FNA.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
FNA vs INSP Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while INSP trades at $58.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas INSP's P/E ratio is 25.62. In terms of profitability, FNA's ROE is -0.35%, compared to INSP's ROE of +0.18%. Regarding short-term risk, FNA is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for FNA.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
FNA vs TNDM Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while TNDM trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas TNDM's P/E ratio is -21.03. In terms of profitability, FNA's ROE is -0.35%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, FNA is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for FNA.Check TNDM's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
FNA vs ATEC Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ATEC trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ATEC's P/E ratio is -162.50. In terms of profitability, FNA's ROE is -0.35%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, FNA is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
FNA vs CNMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CNMD trades at $49.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CNMD's P/E ratio is 10.94. In terms of profitability, FNA's ROE is -0.35%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, FNA is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CNMD's competition here
Enovis Corporation (NYSE: ENOV)
FNA vs ENOV Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ENOV trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ENOV's P/E ratio is 7.36. In terms of profitability, FNA's ROE is -0.35%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, FNA is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
FNA vs IART Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while IART trades at $18.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas IART's P/E ratio is 7.73. In terms of profitability, FNA's ROE is -0.35%, compared to IART's ROE of -0.01%. Regarding short-term risk, FNA is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for FNA.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
FNA vs AORT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while AORT trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas AORT's P/E ratio is 47.38. In terms of profitability, FNA's ROE is -0.35%, compared to AORT's ROE of -0.01%. Regarding short-term risk, FNA is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
FNA vs HSKA Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas HSKA's P/E ratio is -62.49. In terms of profitability, FNA's ROE is -0.35%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, FNA is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for FNA.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
FNA vs PRCT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PRCT trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PRCT's P/E ratio is -11.31. In terms of profitability, FNA's ROE is -0.35%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, FNA is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
FNA vs AVNS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas AVNS's P/E ratio is 27.77. In terms of profitability, FNA's ROE is -0.35%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, FNA is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for FNA.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
FNA vs LMRI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while LMRI trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas LMRI's P/E ratio is -22.82. In terms of profitability, FNA's ROE is -0.35%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, FNA is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for FNA.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
FNA vs SILK Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SILK's P/E ratio is -18.96. In terms of profitability, FNA's ROE is -0.35%, compared to SILK's ROE of -0.35%. Regarding short-term risk, FNA is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for FNA.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
FNA vs IRMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while IRMD trades at $87.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas IRMD's P/E ratio is 43.80. In terms of profitability, FNA's ROE is -0.35%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, FNA is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check IRMD's competition here
Bioventus Inc. (NASDAQ: BVS)
FNA vs BVS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BVS has a market cap of 941M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BVS trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BVS's P/E ratio is 18.28. In terms of profitability, FNA's ROE is -0.35%, compared to BVS's ROE of +0.28%. Regarding short-term risk, FNA is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
FNA vs CBLL Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CBLL has a market cap of 882.2M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CBLL trades at $23.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CBLL's P/E ratio is -14.26. In terms of profitability, FNA's ROE is -0.35%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, FNA is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CBLL's competition here
InMode Ltd. (NASDAQ: INMD)
FNA vs INMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while INMD trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas INMD's P/E ratio is 10.56. In terms of profitability, FNA's ROE is -0.35%, compared to INMD's ROE of +0.12%. Regarding short-term risk, FNA is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
FNA vs AVR Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, AVR has a market cap of 868.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while AVR trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas AVR's P/E ratio is -4.00. In terms of profitability, FNA's ROE is -0.35%, compared to AVR's ROE of -0.78%. Regarding short-term risk, FNA is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for FNA.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
FNA vs CSII Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CSII's P/E ratio is -20.83. In terms of profitability, FNA's ROE is -0.35%, compared to CSII's ROE of -0.14%. Regarding short-term risk, FNA is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for FNA.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
FNA vs SIBN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SIBN has a market cap of 840.4M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SIBN trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SIBN's P/E ratio is -55.74. In terms of profitability, FNA's ROE is -0.35%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, FNA is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check SIBN's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
FNA vs BBNX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BBNX has a market cap of 813.4M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BBNX trades at $18.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BBNX's P/E ratio is -11.97. In terms of profitability, FNA's ROE is -0.35%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, FNA is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BBNX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
FNA vs VREX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, VREX has a market cap of 778.9M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while VREX trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas VREX's P/E ratio is 19.47. In terms of profitability, FNA's ROE is -0.35%, compared to VREX's ROE of +0.05%. Regarding short-term risk, FNA is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for FNA.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
FNA vs AHCO Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while AHCO trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas AHCO's P/E ratio is 11.63. In terms of profitability, FNA's ROE is -0.35%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, FNA is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for FNA.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
FNA vs SSII Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SSII has a market cap of 766.5M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SSII trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SSII's P/E ratio is -74.70. In terms of profitability, FNA's ROE is -0.35%, compared to SSII's ROE of -0.27%. Regarding short-term risk, FNA is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for FNA.Check SSII's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
FNA vs BWAY Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BWAY has a market cap of 646M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BWAY trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BWAY's P/E ratio is 41.84. In terms of profitability, FNA's ROE is -0.35%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, FNA is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
FNA vs KIDS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, KIDS has a market cap of 642.4M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while KIDS trades at $25.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas KIDS's P/E ratio is -21.19. In terms of profitability, FNA's ROE is -0.35%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, FNA is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for FNA.Check KIDS's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
FNA vs CTKB Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CTKB has a market cap of 631.5M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CTKB trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CTKB's P/E ratio is -25.91. In terms of profitability, FNA's ROE is -0.35%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, FNA is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
FNA vs SRDX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SRDX's P/E ratio is -34.66. In terms of profitability, FNA's ROE is -0.35%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, FNA is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for FNA.Check SRDX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
FNA vs DCTH Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, DCTH has a market cap of 599.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while DCTH trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas DCTH's P/E ratio is 1736.00. In terms of profitability, FNA's ROE is -0.35%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, FNA is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for FNA.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
FNA vs APEN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas APEN's P/E ratio is -9.43. In terms of profitability, FNA's ROE is -0.35%, compared to APEN's ROE of -0.85%. Regarding short-term risk, FNA is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check APEN's competition here
Cerus Corporation (NASDAQ: CERS)
FNA vs CERS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CERS has a market cap of 572.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CERS trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CERS's P/E ratio is -56.69. In terms of profitability, FNA's ROE is -0.35%, compared to CERS's ROE of -0.10%. Regarding short-term risk, FNA is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CERS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
FNA vs ZIMV Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, FNA's ROE is -0.35%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, FNA is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for FNA.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
FNA vs TCMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, TCMD has a market cap of 534.8M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while TCMD trades at $23.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas TCMD's P/E ratio is 26.94. In terms of profitability, FNA's ROE is -0.35%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, FNA is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
FNA vs NPCE Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, NPCE has a market cap of 494.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while NPCE trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas NPCE's P/E ratio is -22.32. In terms of profitability, FNA's ROE is -0.35%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, FNA is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for FNA.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
FNA vs CLPT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CLPT has a market cap of 462.4M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CLPT trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CLPT's P/E ratio is -13.07. In terms of profitability, FNA's ROE is -0.35%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, FNA is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
FNA vs SGHT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SGHT has a market cap of 452.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SGHT trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SGHT's P/E ratio is -14.86. In terms of profitability, FNA's ROE is -0.35%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, FNA is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
FNA vs OFIX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, OFIX has a market cap of 411.5M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while OFIX trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas OFIX's P/E ratio is -13.30. In terms of profitability, FNA's ROE is -0.35%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, FNA is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for FNA.Check OFIX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
FNA vs CARL Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CARL has a market cap of 380.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CARL trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CARL's P/E ratio is -9.78. In terms of profitability, FNA's ROE is -0.35%, compared to CARL's ROE of -0.38%. Regarding short-term risk, FNA is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
FNA vs PACB Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PACB's P/E ratio is -2.80. In terms of profitability, FNA's ROE is -0.35%, compared to PACB's ROE of -49.62%. Regarding short-term risk, FNA is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PACB's competition here
Picard Medical, Inc. (AMEX: PMI)
FNA vs PMI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PMI has a market cap of 354.8M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PMI trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PMI's P/E ratio is -2.88. In terms of profitability, FNA's ROE is -0.35%, compared to PMI's ROE of +4.99%. Regarding short-term risk, FNA is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PMI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
FNA vs CATX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CATX has a market cap of 352.4M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CATX trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CATX's P/E ratio is -2.19. In terms of profitability, FNA's ROE is -0.35%, compared to CATX's ROE of -0.42%. Regarding short-term risk, FNA is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CATX's competition here
Electromed, Inc. (AMEX: ELMD)
FNA vs ELMD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ELMD has a market cap of 351.1M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ELMD trades at $42.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ELMD's P/E ratio is 36.24. In terms of profitability, FNA's ROE is -0.35%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, FNA is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
FNA vs TLSI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, TLSI has a market cap of 346.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while TLSI trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas TLSI's P/E ratio is -3.35. In terms of profitability, FNA's ROE is -0.35%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, FNA is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for FNA.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
FNA vs CV Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, CV has a market cap of 339.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while CV trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas CV's P/E ratio is -2.72. In terms of profitability, FNA's ROE is -0.35%, compared to CV's ROE of +1.27%. Regarding short-term risk, FNA is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for FNA.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
FNA vs SENS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SENS has a market cap of 323.1M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SENS trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SENS's P/E ratio is -3.86. In terms of profitability, FNA's ROE is -0.35%, compared to SENS's ROE of -1.66%. Regarding short-term risk, FNA is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for FNA.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
FNA vs SMLR Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas SMLR's P/E ratio is 3.92. In terms of profitability, FNA's ROE is -0.35%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, FNA is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for FNA.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
FNA vs TMCI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while TMCI trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas TMCI's P/E ratio is -4.80. In terms of profitability, FNA's ROE is -0.35%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, FNA is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for FNA.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
FNA vs RXST Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, RXST has a market cap of 290.2M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while RXST trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas RXST's P/E ratio is -7.54. In terms of profitability, FNA's ROE is -0.35%, compared to RXST's ROE of -0.17%. Regarding short-term risk, FNA is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for FNA.Check RXST's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
FNA vs ANIK Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ANIK has a market cap of 283.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ANIK trades at $21.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ANIK's P/E ratio is 43.20. In terms of profitability, FNA's ROE is -0.35%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, FNA is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for FNA.Check ANIK's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
FNA vs MGRM Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas MGRM's P/E ratio is -12.00. In terms of profitability, FNA's ROE is -0.35%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, FNA is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for FNA.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
FNA vs PROF Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, PROF has a market cap of 242.4M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while PROF trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas PROF's P/E ratio is -5.38. In terms of profitability, FNA's ROE is -0.35%, compared to PROF's ROE of -0.56%. Regarding short-term risk, FNA is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for FNA.Check PROF's competition here
Nevro Corp. (NYSE: NVRO)
FNA vs NVRO Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas NVRO's P/E ratio is -1.91. In terms of profitability, FNA's ROE is -0.35%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, FNA is similarly volatile compared to NVRO. This indicates similar risk in terms of short-term price fluctuations for FNA.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
FNA vs STIM Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, STIM has a market cap of 210.9M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while STIM trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas STIM's P/E ratio is -5.61. In terms of profitability, FNA's ROE is -0.35%, compared to STIM's ROE of -1.51%. Regarding short-term risk, FNA is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for FNA.Check STIM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
FNA vs RCEL Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, RCEL has a market cap of 199M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while RCEL trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas RCEL's P/E ratio is -5.10. In terms of profitability, FNA's ROE is -0.35%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, FNA is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for FNA.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
FNA vs BSGM Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas BSGM's P/E ratio is -5.81. In terms of profitability, FNA's ROE is -0.35%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, FNA is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for FNA.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
FNA vs LUCD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, LUCD has a market cap of 184.1M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas LUCD's P/E ratio is -2.61. In terms of profitability, FNA's ROE is -0.35%, compared to LUCD's ROE of -0.02%. Regarding short-term risk, FNA is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for FNA.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
FNA vs MDGS Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas MDGS's P/E ratio is -0.27. In terms of profitability, FNA's ROE is -0.35%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, FNA is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for FNA.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
FNA vs FOCL Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while FOCL trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas FOCL's P/E ratio is -5.80. In terms of profitability, FNA's ROE is -0.35%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, FNA is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for FNA.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
FNA vs QIPT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas QIPT's P/E ratio is -15.87. In terms of profitability, FNA's ROE is -0.35%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, FNA is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for FNA.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
FNA vs INGN Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, INGN has a market cap of 157.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while INGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas INGN's P/E ratio is -6.38. In terms of profitability, FNA's ROE is -0.35%, compared to INGN's ROE of -0.13%. Regarding short-term risk, FNA is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for FNA.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
FNA vs QTRX Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, QTRX has a market cap of 134.7M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while QTRX trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas QTRX's P/E ratio is -1.79. In terms of profitability, FNA's ROE is -0.35%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, FNA is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for FNA.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
FNA vs OWLT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, OWLT has a market cap of 114.5M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while OWLT trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas OWLT's P/E ratio is -45.21. In terms of profitability, FNA's ROE is -0.35%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, FNA is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
FNA vs ICAD Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas ICAD's P/E ratio is -20.37. In terms of profitability, FNA's ROE is -0.35%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, FNA is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for FNA.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
FNA vs HSDT Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, HSDT has a market cap of 105.1M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while HSDT trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas HSDT's P/E ratio is -0.02. In terms of profitability, FNA's ROE is -0.35%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, FNA is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for FNA.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
FNA vs HJLI Comparison August 2026
Paragon 28, Inc. (NYSE: FNA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FNA stands at 1.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, FNA is priced at $13.09 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FNA currently has a P/E ratio of -19.83, whereas HJLI's P/E ratio is N/A. In terms of profitability, FNA's ROE is -0.35%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, FNA is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for FNA.Check HJLI's competition here